The goal of this study was to investigate the binding characteristics of [ 11 C]KR31173 and its applicability for PET studies of the AT 1 receptor (AT 1 R).
Methods-Exvivo biodistribution and pharmacology were tested in mice. PET imaging was performed in mice, beagle dogs, and a baboon. To assess nonspecific binding, PET imaging was performed both before and after pretreatment with a potent AT 1 R antagonist. In the baboon, PET imaging was also performed with the previously developed radioligand [ 11 C]L-159,884 for comparison.Results-Ex vivo biodistribution studies in mice showed specific binding rates of 80-90% in the adrenals, kidneys, lungs, and heart. Specific binding was confirmed in mice using small animal PET. In dogs, renal cortex tissue concentration at 75-95 min post-injection was 63 nCi/mL/mCi at a specific binding rate of 95%. In the baboon renal cortex, tissue activity at 55-75 min post injection was 345 nCi/mL/mCi. The specific binding of [ 11 C]KR31173 was higher (81%) in the baboon than the specific binding of [ 11 C]L-159,884 (34%).
Conclusion-[11 C]KR31173 shows accumulation and significant specific binding to the AT 1 R in the kidneys of mice, dogs, and baboon. These findings suggest that this radioligand is suited for imaging the renal cortical AT 1 R in multiple species.